✦ LIBER ✦

HBeAg-Negative Chronic Hepatitis B: Cost-Effectiveness of Peginterferon Alfa-2a Compared to Lamivudine in Taiwan

✍ Scribed by David L. Veenstra; Sean D. Sullivan; Ming-Yang Lai; Chuan-Mo Lee; Chia-Ming Tsai; Kavita K. Patel

Book ID: 109078683
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 184 KB
Volume: 11
Category: Article
ISSN: 1098-3015
DOI: 10.1111/j.1524-4733.2007.00221.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness of peginterferon alfa

Cost-effectiveness of peginterferon alfa-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan

✍ Sean D Sullivan; David L Veenstra; Pei-Jer Chen; Ting-Tsung Chang; Wan-Long Chua 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

Lamivudine/pegylated interferon alfa-2b

Lamivudine/pegylated interferon alfa-2b sequential combination therapy compared with lamivudine monotherapy in HBeAg-negative chronic hepatitis B

✍ Themistoklis Vassiliadis; Konstantinos Tziomalos; Kalliopi Patsiaoura; Thomas Za 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

Randomised clinical trial: efficacy of p

Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance

✍ J. Sun; J.-L. Hou; Q. Xie; X.-H. Li; J.-M. Zhang; Y.-M. Wang; H. Wang; J.-Y. Lai 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB

Hepatitis B virus surface antigen levels

Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B

✍ Maurizia Rossana Brunetto; Francesco Moriconi; Ferruccio Bonino; George K. K. La 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 748 KB

Bristol-Myers Squibb, Gilead, and Novartis. He is also in the speakers' bureau of Schering-Plough. Dr. Lau is on the speakers' bureau of and received grants from Roche and Novartis. Dr. Piratvisuth advises and is on the speakers' bureau of Roche. He advises Novartis and Schering-Plough and is on th

Early serum HBsAg level as a strong pred

Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B

✍ C.-Y. Peng; H.-C. Lai; Y.-F. Li; W.-P. Su; P.-H. Chuang; J.-T. Kao 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB

Cost-effectiveness analysis of lamivudin

Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B

✍ M. BUTI; M. A. CASADO; J. L. CALLEJA; J. SALMERÓN; J. AGUILAR; M. RUEDA; R. ESTE 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB